Cheng-Feng Qin and Gong Cheng for providing the Zika disease isolate GZ01 and for assisting with evaluations of antibody protective activity in AG6 mice. mice, and markedly reduced cells pathology in infected mice. Thus, ZK2B10 is definitely a promising candidate for the development of antibody-based interventions and informs the rational design of ZIKV vaccine. Keywords:Zika disease, microcephaly, neutralizing antibody, epitope, vaccine, neural progenitor cells, safety == Graphical Abstract == Zika disease (ZIKV) is definitely a mosquito-transmitted flavivirus that can cause severe neurological problems in humans. Li et al. have identified a human being monoclonal antibody capable of safety against ZIKV illness and NES related diseases when tested in mouse models. This antibody serves as a encouraging candidate for medical development against ZIKV. == Intro == The recent, common neurological deficits caused by an emergent strain of Zika disease (ZIKV) have caught the world off guard (Petersen et al., 2016,Wikan and Smith, 2016). ZIKV was first recognized in the forests of Uganda, and illness was generally benign in humans (Dick et al., 1952). However, this new strain of ZIKV is definitely far more virulent and causes a range of medical anomalies (Petersen et al., 2016,Rasmussen et al., 2016,Wikan and Smith, 2016). Most notable are microcephaly and additional congenital problems in infants created to mothers infected with ZIKV during pregnancy (Mlakar et al., 2016,Petersen et al., 2016,Rasmussen et al., 2016,Wikan and Smith, 2016). Although the exact mechanism of neuropathogenesis remains uncertain, medical abnormalities have been linked to the aberrant development and loss of neural progenitor cells (NPCs) (Cugola et al., 2016,Gabriel et al., 2017,Garcez et al., 2016,Li et al., 2016a,Li et al., 2016b,Tang et al., 2016). The contemporary strain of ZIKV offers enhanced replication capacity and a specialized tropism for NPCs (Cugola et al., 2016,Dang et al., 2016,Garcez et al., 2016,Li et al., 2016b,Tang et al., 2016), although other types of cells are vulnerable (Tabata et al., 2016,Weisblum et al., 2017). The infection inhibits NPC proliferation and differentiation and may result in apoptosis or autophagy. Critically, the highest rates of birth problems happen in pregnant mothers who are infected during their Ethynylcytidine 1st and second trimesters. This is presumably because, during the early stages of gestation, NPCs have a greater susceptibility to ZIKV illness, and there is more viral transfer across the placental barrier (Mlakar et al., 2016,Petersen et al., 2016,Rasmussen et al., 2016,Wikan and Smith, 2016). To fully guard the developing fetuses, an treatment must happen before this period or, ideally, prior to illness (Marston et al., 2016). Neutralizing antibodies are the essential mediator of immunity against viral illness (Burton and Hangartner, 2016,Corti and Lanzavecchia, 2013). For ZIKV and additional flaviviruses, human being neutralizing monoclonal antibodies target the surface envelope glycoprotein (E) that facilitates illness (Dejnirattisai et al., 2015,Dowd et al., 2011,Dowd and Pierson, 2011,Fernandez et al., 2017,Fibriansah et al., 2015,Heinz and Stiasny, 2012,Magnani et al., 2017,Pierson and Diamond, 2008,Pierson and Graham, 2016,Robbiani et al., 2017,Rogers et al., 2017,Sapparapu et al., 2016,Stettler et al., Ethynylcytidine 2016,Wang et al., 2016,Wang et al., 2017b,Zhao et al., 2016). We previously reported on Ethynylcytidine a panel of monoclonal antibodies (mAbs) derived from the longitudinal samples of a ZIKV-convalescent individual and characterized their neutralizing activities, epitope specificities, and development timeline over the course of illness (Yu et al., 2017). We also reported on mouse models of ZIKV illness and microcephaly, with enhanced specificity for neurological illness using a contemporary ZIKV Asian strain (GZ01). In the model of microcephaly, the disease was inoculated directly into the lateral ventricles of the fetal mouse mind (Li et al., 2016a). ZIKV replicated in the fetal mind, with preferential illness of NPCs. Illness resulted in cell-cycle arrest, differentiation problems, and a large number of cell deaths, as well as medical presentations of microcephaly (Li et al., 2016a). Here, we use the mouse models of ZIKV illness and microcephaly to analyze thein vivoprotective activities of six human being mAbs and compare the findings with our reportedin vitroneutralization Ethynylcytidine activity, as measured by plaque reduction neutralization test (PRNT). Our results offer compelling evidence that thein vivoprotection.